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Tumour-associated microglia/macrophages predict poor prognosis in high-grade gliomas and
correlate with an aggressive tumour subtype
Aims: Glioblastomas are highly aggressive and treat-
ment resistant. Increasing evidence suggests that
tumour-associated macrophages/microglia (TAMs) facil-
itate tumour progression by acquiring a M2-like pheno-
type. Our objective was to investigate the prognostic
value of TAMs in gliomas using automated quantitative
double immunofluorescence. Methods: Samples from
240 patients with primary glioma were stained with
antibodies against ionized calcium-binding adaptor
molecule-1 (IBA-1) and cluster of differentiation 204
(CD204) to detect TAMs and M2-like TAMs. The
expression levels were quantified by software-based
classifiers. The associations between TAMs, gemisto-
cytic cells and glioblastoma subtype were examined
with immuno- and haematoxylin–eosin stainings.
Three tissue arrays containing glioblastoma specimens
were included to study IBA-1/CD204 levels in central
tumour and tumour periphery and to characterize
CD204+ cells. Results: Our data revealed that the
amount of especially CD204+ TAMs increases with
malignancy grade. In grade III–IV, high CD204 expres-
sion was associated with shorter survival, while high
IBA-1 intensity correlated with a longer survival. In
grade IV, CD204 showed independent prognostic value
when adjusting for clinical data and the methylation
status of O6-methylguanine–DNA methyltransferase.
Our findings were confirmed in two bioinformatics
databases. TAMs were more abundant in central
tumour tissue, mesenchymal glioblastomas and gliomas
with many gemistocytic cells. CD204+ TAMs co-
expressed proteins related to tumour aggressiveness
including matrix metallopeptidase-14 and hypoxia-
inducible factor-1a. Conclusions: This is the first study
to use automated quantitative immunofluorescence to
determine the prognostic impact of TAMs. Our results
suggest that M2-like TAMs hold an unfavourable prog-
nostic value in high-grade gliomas and may contribute
to a pro-tumourigenic microenvironment.
Keywords: CD204, glioblastoma, glioma, macrophages, microglia, prognosis
Introduction
Gliomas are the most common primary brain tumours
in adults. Patient prognosis differs considerably within
the different World Health Organization (WHO) grades
being poorest for patients with the grade IV tumour –
the glioblastoma multiforme (GBM). In 2005, temozolo-
mide was introduced as supplement to standard treat-
ment of GBM patients [1] resulting in improved
survival, especially for patients with methylated O6-
methylguanine–DNA methyltransferase (MGMT) pro-
moter [2–4]. Additional therapeutic strategies have not
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been able to further improve prognosis, and the 2- and
5-year survival remain below 25% and 10%, respec-
tively [3,4]. The inefficacy may be explained by several
mechanisms of resistance [4,5], and increasing evi-
dence suggests that factors in the tumour microenvi-
ronment including hypoxia and nonneoplastic cells
may constitute extrinsic resistance mechanisms [6].
The tumour microenvironment could, thus, be a target
for anticancer therapy.
In removed GBM tissue, tumour-associated micro-
glia/macrophages (TAMs) have been reported to consti-
tute up to 30% [7–10]. TAMs are recruited from the
brain and bone marrow to the site of the tumour
through the action of signalling molecules released by
glioma cells and other cells in the microenvironment
[8,9,11,12]. Reportedly, glioma cells suppress the
immune surveillance of TAMs by skewing them
towards the pro-tumourigenic M2 phenotype while
inhibiting development of the anti-tumourigenic M1
phenotype [8,9,13–16]. However, recent studies indi-
cate that glioma cells induce a mixed population of
TAMs expressing both M1- and M2-related molecules
[11,17–20] possibly resembling a more undifferentiated
M0 phenotype [21]. In return, TAMs support tumour
growth and progression [8–10] by stimulating prolifera-
tion [22], migration [23,24], invasion [12,22–25] and
angiogenesis [8,9,26], overall indicating a complex bidirec-
tional communication between glioma cells and TAMs.
Using immunohistochemistry, the number of TAMs
was shown to increase with malignancy grade in glio-
mas [15,27,28]. In addition, high amounts of TAMs
expressing M2-related markers, e.g. cluster of differentia-
tion 204 (CD204) and 163 (CD163), have been associ-
ated with increasing WHO grade and poorer prognosis
[15,29,30]. However, these studies neither investigated
the influence of M2 TAMs on survival in separate WHO
grades nor performed multivariate analysis to examine
the independent prognostic value. Based on these unre-
solved issues, our aim was to explore the prognostic
impact of TAMs in a large population-based glioma
cohort by quantifying the expression of the microglial/
macrophage markers ionized calcium-binding adaptor
molecule-1 (IBA-1) and CD204 using double
immunofluorescence. IBA-1 is considered a specific TAM
marker [31] and CD204 a marker of M2-like TAMs [9].
We used an automated quantitative fluorescence
approach enabling continuous measurements of area
and intensity reducing some of the inter- and intra-
observer variability seen in conventional semi-quantita-
tive pathologist-based scoring [32,33]. Early on, we dis-
covered that the distribution of TAMs in especially GBMs
was highly heterogeneous. We, therefore, investigated
the correlation between TAMs, gemistocytic tumour cells
and GBM subtype as tumour aggressiveness may depend
on both the specific molecular subtype and the level of
gemistocytic tumour cells. In addition, we characterized
the phenotype of CD204+ TAMs by double immunofluo-
rescence using a panel of eight markers related to
immune activation and tumour aggressiveness.
Materials and methods
Patient tissue
Samples were obtained from the Region of Southern
Denmark (RSD) glioma cohort investigated and well-
characterized previously [34–40]. Tissue from 240
patients was included for the IBA-1/CD204 analysis.
All patients were diagnosed with a primary glioma
between 2005 and 2009. Table S1 provides an over-
view of relevant patient characteristics including clini-
cal and histological data. A tissue array containing
eight GBM specimens was included to study the expres-
sion of IBA-1/CD204 in central tumour and tumour
periphery. In addition, two tissue arrays with 34 GBM
specimens were included to characterize CD204+ cells.
All samples were evaluated by two pathologists and re-
classified according to WHO guidelines 2016 [41]. See
Data S1 for information on procedures used for re-
classification.
Normal brain tissue was obtained from two adult
patients at autopsy. Cause of death was unrelated to
any disease in the central nervous system (CNS). Tissue
was obtained from 10 patients with primary diffuse
large B-cell lymphoma (DLBCL) in the CNS, 10 patients
diagnosed with first-time CNS metastasis from malig-
nant melanoma (MM), and 10 patients diagnosed with
first-time CNS metastasis from non-small cell lung can-
cer (NSCLC).
Double immunofluorescence
Immunofluorescence stainings were performed as previ-
ously reported [34,35,42,43]. See Data S1 for informa-
tion on the staining procedure and Table S2 for
information on antibodies used.
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Automated quantitative fluorescence analysis
Fluorescence image analysis and quantitation were done
using the Visiopharm integrated microscope and soft-
ware module (Visiopharm, Hørsholm, Denmark) consist-
ing of a Leica DM 6000B microscope and Olympus DP72
camera (Olympus, Ballerup, Denmark). Super images
were acquired at 1.259 magnification using bright field
settings, and sampling regions containing vital tumour
tissue were manually outlined. Sample images were col-
lected by systematic uniform random sampling at 209
magnification. Images were reviewed ensuring at least
five images per tumour, and only images with at least
20% viable tumour tissue within the picture frame were
included for further processing. Images were classified
using algorithms developed in the Visiomorph module.
Individual pixels were assigned labels based on threshold
intensities of the colour bands. To quantify the expres-
sions of IBA-1 and CD204, the tumour area within each
picture frame was defined manually as a region of inter-
est (ROI). For the quantification of double-positive
expression (i.e. IBA-1+ CD204+ pixels), IBA-1 was used
as an inclusion marker and defined as a ROI, then the
expression of CD204 was evaluated within this ROI
enabling measurements of double-labelled protein
expression (Figure 1). Output variables were area frac-
tions (AF), defined as area of positive expression divided
by the area of the respective ROI, and mean intensity
(MI) of IBA-1 and CD204 in total tumour tissue as well
as of CD204 within the IBA-1+ area (i.e. IBA-1TOTAL,
CD204TOTAL and CD204IBA-1). Prior to sampling, calibra-
tion was performed to adjust for run variation within the
staining. This was accomplished using adjacent sections
of a GBM tissue array (Figure S1).
Similar algorithms were generated to characterize
the phenotype of the CD204+ cells. The area of double-
stained area was quantified as a fraction of the total
CD204+ area resulting in a quantitative estimate of
double-positive cells. In addition, the intensity of the
marker of interest was measured in the total CD204+
area.
MGMT status
O6-methylguanine–DNA methyltransferase promoter
status was retrospectively obtained in 161 patients
using pyrosequencing (QIAamp DNA FFPE Tissue kit;
Qiagen, Hilden, Germany) as previously described [39].
Gemistocytic cell component
Presence of gemistocytic tumour cells (gemistocytes) was
evaluated in 11 diffuse astrocytomas (DA), 17 anaplastic
astrocytomas (AAs) and 20 GBMs from the RSD glioma
cohort using haematoxylin–eosin stainings. The 20
GBMs represented 10 of the patients with the lowest and
10 of the patients with the highest AF CD204TOTAL. All
samples were scored blinded and semi-quantitatively. At
409 magnification, five positions per slide were scored
from 0 to 4 (0: no gemistocytes; 1: <10%; 2: 10–49%; 3:
50–90%; 4: >90% gemistocytes), and a mean score was
calculated for each tumour.
Immunohistochemical subtyping
The association between TAMs and molecular subtype
was investigated by staining the 20 GBM samples
described above with three proneural markers: delta-like
3, NEUronal Nuclei and oligodendrocyte transcription
factor 2 (OLIG-2), as well as three mesenchymal markers:
CD44, vascular endothelial growth factor (VEGF) and
chitinase 3-like 1 (YKL-40/CHI3L1) [44–47]. Immuno-
histochemistry was performed as previously described
[36,37,39,40]. The tumours were scored and indexed as
proneural or mesenchymal as previously reported [44].
See Data S1 for information on the staining procedure
and Table S2 for information on antibodies used.
Patient dataset analysis
mRNA expressions of IBA-1 (AIF-1) and CD204 (MSR-
1) in gliomas were explored using GlioVis (https://glio
vis.bioinfo.cnio.es, data were exported July 2016). From
the Cancer Genome Atlas (TCGA), mRNA data were
available for 620 patients for analysing the association
with malignancy grade [48] and for 460 GBM patients
(the Agilent 4502SA dataset) for survival and subtype
analyses [49]. From the Glavendel dataset, mRNA data
were obtained for 276 patients including 159 GBM
patients [50]. Datasets were exported directly from Glio-
Vis. Survival analyses were carried out using the me-
dian as cut-off value.
Statistical analysis
Student’s t-test or Mann–Whitney U-test was used when
comparing two groups. One-way ANOVA with Bonferroni’s
© 2017 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society
NAN 2018; 44: 185–206
Microglia/macrophages in gliomas 187
correction or Kruskal–Wallis test followed by Dunn’s
multiple comparisons test was used for comparison of
more than two groups. Correlation analyses were per-
formed using Spearman’s correlation test. Overall sur-
vival (OS) was defined as time from primary surgery
until death or date of censoring (May 2017). Survival
functions were illustrated by Kaplan–Meier plots, and dif-
ferences were compared by log-rank tests. WHO grade I
was excluded in the statistical analysis due to limited
numbers (n = 3). CD204 and IBA-1 estimates were
investigated as binary variables with the median as a
prespecified cut-off value. Exploratory cut-point analyses
were performed for grade IV as previously described
[34,40], and only results using the optimal cut-points
are shown. Multivariate analyses were performed using
the Cox proportional hazard model.
All assumptions were tested. Statistical analyses were
carried out in STATA (StataCorp LP) or Prism 5.0
(A) (D)
(B)
(C)
(E) (F) (G)
Figure 1. Image recording and classification. (A–D) Each image was recorded as three separate greyscale images for cyanine 5 [ionized
calcium-binding adaptor molecule-1 (IBA-1)] (A), fluorescein (CD204) (B) and DAPI (nuclei) (C) and subsequently assigned colours and
superimposed to form the complete image (D). Images were then classified by three classifiers based on threshold intensities of the colour
bands. (E,F) To quantify the total expression of IBA-1 (IBA-1TOTAL) and CD204 (CD204TOTAL), the tumour area within each picture frame
was defined as region of interest (ROI) with digital image analysis. (G) For the quantification of double-positive expression (i.e. IBA-1+
CD204+), IBA-1 was used as an inclusion marker and defined as a ROI, and then the expression of CD204 was evaluated within this ROI
enabling measurements of double-labelled protein expression (CD204IBA-1).
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(GraphPad Software Inc., San Diego, CA, USA). P-values
<0.05 were considered significant.
Results
Expression of CD204 and IBA-1 in gliomas, normal
brain, and other brain neoplasms
CD204 and IBA-1 were expressed in the membrane
and cytoplasm of TAMs including their ramifications
(Figure 2A–I). In pilocytic astrocytomas, the amount
of IBA-1+ cells was moderate to high while few cells
expressed CD204 (Figure 2A). Diffuse astrocytomas
and oligodendrogliomas (OD) showed moderate IBA-1
and sparse CD204 expression (Figure 2B–D). AAs
had moderate to high levels of IBA-1+ cells with
some CD204+ cells, especially in isocitrate dehydroge-
nase (IDH) wild-type tumours, (Figure 2E,F), whereas
anaplastic OD had lower IBA-1 levels compared with
AAs with limited expression of CD204 (Figure 2G).
GBM (Figure 2H) and especially gliosarcomas (Fig-
ure 2I) exhibited high expression of IBA-1 and/or
CD204.
When applying the software-based classifiers, all
quantitative estimates except MI IBA-1TOTAL
(P = 0.084) showed overall significant increases with
malignancy grade (P < 0.001) being significantly high-
est in grade IV tumours (Figure 2J,K). In grade IV, the
IBA-1+ area contributed with up to 0.30 of the total
tumour area (median: 0.10), while the CD204+ area
comprised up to 0.24 (median = 0.048). On average,
50% of the IBA-1+ area co-localized with CD204 (me-
dian = 0.45), but up to 90% co-expression was
observed (Figure 2J).
To explore whether the vast existence of TAMs was
specific to gliomas, expression levels of IBA-1 and
CD204 were investigated in normal brain tissue, in tis-
sue from primary brain DLBCL and metastases from
NSCLC and MM (Figure S2A-H). AF IBA-1TOTAL and
MI IBA-1TOTAL were highest in gliomas compared with
normal brain, MM and DLBCL (P < 0.001), as well as
NSCLC (P < 0.01 and <0.001). AF CD204TOTAL was
lower in normal brain (P < 0.001) and in DLBCL
(P < 0.05) compared with gliomas, and gliomas had
the highest MI CD204TOTAL (P < 0.05). Similar was
found for AF CD204IBA-1 and MI CD204IBA-1, except
for NCSLC which did not differ significantly from glio-
mas (Figure S2G,H).
TAMs and survival in WHO grade II–IV gliomas
Investigating the association between TAMs and prog-
nosis in grade II-IV gliomas, high AF IBA-1TOTAL was
significantly associated with shorter OS when dichoto-
mized at the median (HR = 1.50; 95% CI: 1.15–1.97;
P = 0.003), while MI IBA-1TOTAL did not correlate
with survival (HR = 0.93; 95% CI: 0.71–1.20;
P = 0.57). High levels of AF CD204TOTAL and MI
CD204TOTAL correlated with poorer prognosis when
divided at the median (HR = 2.02; 95% CI: 1.54–
2.67; P < 0.001 and HR = 1.85; 95% CI: 1.41–2.42;
P < 0.001). Similar was found for AF CD204IBA-1 and
MI CD204IBA-1 (HR = 1.93; 95% CI: 1.48–2.53; P
< 0.001 and HR = 1.92; 95% CI: 1.47–2.51;
P < 0.001). In the multivariate analyses, high levels
of AF CD204TOTAL (HR = 1.81; 95% CI: 1.35–2.44;
P < 0.001) and AF CD204IBA-1 (HR = 1.25; 95% CI:
1.01–1.81; P = 0.042) correlated with shorter OS
(Table S3).
TAMs and survival in WHO grade II–III
In WHO grade II, neither IBA-1 nor CD204 expression
levels were associated with prognosis when dichoto-
mized at the median (Figure S3A–D). When adjusting
for performance status, IDH status and histology in the
multivariate analysis, high AF IBA-1TOTAL correlated
with better prognosis, while CD204 did not impact
prognosis (Table S4).
In WHO grade III, no prognostic value was found for
AF IBA-1TOTAL when dichotomized at median (Fig-
ure S3E). High levels of MI IBA-1TOTAL tended to associ-
ate with longer OS (Figure S3F), while high CD204
levels correlated significantly with shorter OS when
divided at the median (Figure S3G,H). When accounting
for performance status, IDH status and histology in the
multivariate analysis, CD204 had a negative prognostic
value (Table S5).
TAMs and survival in WHO grade IV
AF IBA-1TOTAL was not associated with prognosis in
univariate (HR = 0.99; 95% CI: 0.74–1.32; P = 0.95)
(Figure 3A) or multivariate analyses (HR = 1.06; 95%
CI: 0.79–1.43; P = 0.68) (Table 1) when dichotomized
at the median, and no optimal cut-points were identi-
fied. High MI IBA-1TOTAL tended to associate with
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(A) (B) (C)
(D) (E) (F)
(G)
(J) (K)
(H) (I)
Figure 2. Expression of ionized calcium-binding adaptor molecule-1 (IBA-1) and CD204 in gliomas. (A–I) Examples of the double
immunofluorescence staining in the different histological subtypes: PA (A), wtIDH DA (B), mIDH DA (C), OD (D), wtIDH AA (E), mIDH
AA (F), AOD (G), GBM (H) and GS (I). Arrows and inserts show double-positive cells. (J) The area fraction of IBA-1TOTAL, CD204TOTAL and
CD204IBA-1 increased with malignancy grade. (K) Mean intensities of CD204TOTAL and CD204IBA-1 were higher in high-grade compared
with low-grade gliomas, while no difference was observed for MI IBA-1TOTAL. Horizontal lines indicate the median. *P < 0.05;
**P < 0.01; ***P < 0.001. Scale bar 100 lM. AA, anaplastic astrocytoma; AOD anaplastic oligodendroglioma; DA, diffuse astrocytoma;
GBM, glioblastoma multiforme; GS, gliosarcoma; mIDH, mutated isocitrate dehydrogenase; OD, oligodendroglioma; PA, pilocytic
astrocytoma; wtIDH, wild-type IDH.
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improved survival when divided at the median (data
not shown). However, 40 patients (21%) had a MI
above 107.0 which was the optimal cut-off, and these
patients survived significantly longer than patients with
a lower intensity (HR = 0.64; 95% CI: 0.45–0.92;
P = 0.014) (Figure 3B), and this was significant in the
Figure 3. Tumour-associated microglia/macrophages and survival in grade IV gliomas. (A) The area fraction of ionized calcium-binding
adaptor molecule-1TOTAL (IBA-1TOTAL) did not influence overall survival, while (B) high mean intensity of IBA-1TOTAL correlated with
better prognosis. (C–D) High area fraction and high mean intensity of CD204TOTAL were associated with poorer prognosis. Patients with
high area fraction of CD204TOTAL and low area fraction of IBA-1TOTAL had poorer outcome and shortest the median survival (E).
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multivariate analysis (HR = 0.66; 95% CI: 0.46–0.95;
P = 0.026) (Table 1).
High levels of AF CD204TOTAL predicted shorter OS
(HR = 1.36; 95% CI: 1.02–1.81; P = 0.038) (Fig-
ure 3C) when dichotomized at the median, which was
the optimal cut-point. This was also significant when
adjusting for the clinical parameters (HR = 1.67; 95%
CI: 1.23–2.27; P = 0.001) (Table 1). High MI
CD204TOTAL tended to correlate with shorter OS when
dichotomized at the median (data not shown). This
association was significant in the univariate
(HR = 2.21; 95% CI: 1.48–3.29; P < 0.001) and mul-
tivariate analysis (HR = 2.27; 95% CI: 1.50–3.43;
P < 0.001) when dividing at the optimal intensity cut-
off of 129.1 corresponding to the 84 percentile (Fig-
ure 3D and Table 1). Similar hazard ratios were found
when examining the prognostic impact of double-posi-
tive TAMs (data not shown).
Dichotomizing patients based on AF IBA-1TOTAL and
AF CD204TOTAL, patients with high CD204 and low
IBA-1 had the poorest prognosis with a median sur-
vival of 5.1 months (P < 0.01) (Figure 3E), suggesting
Table 1. Multivariate Cox regression analyses of IBA-1 and CD204 levels in patients with WHO grade IV tumours including clinical
parameters
No. of patients
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Baseline model AF IBA-1TOTAL MI IBA-1TOTAL
Age 192 1.01 (0.99–1.02) 0.22 1.01 (0.99–1.03) 0.20 1.01 (0.99–1.02) 0.32
Performance status
0–1 121 1.00 1.00 1.00
2–4 71 1.39 (1.23–1.58) <0.001 1.39 (1.23–1.58) <0.001 1.38 (1.22–1.57) <0.001
Tumour crossing midline
No 174 1.00 1.00 1.00
Yes 18 1.24 (0.73–2.09) 0.43 1.23 (0.73–2.08) 0.43 1.24 (0.74–2.09) 0.42
Postsurgical treatment
Stupp* 105 1.00 1.00 1.00
PC† 53 1.76 (1.24–2.51) 0.002 1.75 (1.23–2.50) 0.002 1.85 (1.30–2.64) 0.001
Non‡ 34 8.90 (5.35–14.8) <0.001 8.83 (5.32–14.7) <0.001 9.33 (5.60–15.5) <0.001
AF/MI
Low – – 1.00 1.00
High – – – 1.06 (0.79–1.43) 0.68 0.66 (0.46–0.95) 0.026
AF CD204TOTAL MI CD204TOTAL
Age 192 – – 1.01 (1.00–1.03) 0.16 1.01 (1.00–1.03) 0.17
Performance status
0–1 121 – 1.00 1.00
2–4 71 – – 1.45 (1.27–1.65) <0.001 1.36 (1.20–1.54) <0.001
Tumour crossing midline
No 174 – 1.00 1.00
Yes 18 – – 1.29 (0.77–2.17) 0.33 1.35 (0.80–2.30) 0.26
Postsurgical treatment
Stupp* 105 – 1.00 1.00
PC† 53 – – 1.92 (1.34–2.75) <0.001 1.74 (1.23–2.48) 0.002
None‡ 34 – – 8.27 (5.01–13.7) <0.001 9.59 (5.70–16.1) <0.001
AF/MI
Low – – 1.00 1.00
High – – – 1.67 (1.23–2.27) 0.001 2.27 (1.50–3.43) <0.001
IBA-1, ionized calcium-binding adaptor molecule-1; WHO, World Health Organization; AF, area fraction; MI, mean intensity; PC, pallia-
tive care.
*Treatment according to the publication by Stupp et al. [1].
†Palliative treatment is radiotherapy alone (60 Gy/30–33 fractions), hypofractionated radiotherapy alone (30–34 Gy/10 fractions),
hypofractionated radiotherapy with chemotherapy, or chemotherapy alone.
‡No postsurgical treatment.
Bold values represent the significant P values (P < 0.05)
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that TAMs with intense expression of CD204 are the
most important prognostic indicator.
TAMs, postsurgical treatment and survival
To further investigate the influence of TAMs, we strati-
fied GBM patients based on postsurgical treatment and
the level of total IBA-1 and CD204. AF IBA-1TOTAL did
not influence OS in the postsurgical-treated patients
(HR = 1.00; 95% CI: 0.85–1.17; P = 0.99) or in
patients only undergoing surgery (HR = 0.98; 95% CI:
0.70–1.38; P = 0.91) (Figure 4A). In the group who
received postsurgical treatment, patients with high MI
IBA-1TOTAL had longer OS than patients with low MI
(HR = 0.78; 95% CI: 0.64–0.95; P = 0.013), while this
correlation was insignificant in patients who only
received surgery (HR = 0.95; 95% CI: 0.63–1.42;
P = 0.79) (Figure 4B). In the group receiving postsur-
gical treatment, high AF CD204TOTAL predicted shorter
OS (HR = 1.20; 95% CI: 1.03–1.42; P = 0.019), while
no difference was found in the group who only under-
went surgery (HR = 0.92; 95% CI: 0.66–1.31;
P = 0.66) (Figure 4C). In the group receiving postsur-
gical treatment, patients with high MI CD204TOTAL had
poorer prognosis compared with patients with low MI
CD204TOTAL (HR = 1.52; 95% CI: 1.21–1.91;
P < 0.001). No difference was found in the group
undergoing surgery only (HR = 1.35; 95% CI: 0.88–
2.07; P = 0.17) (Figure 4D).
TAMs, MGMT status and survival
The association between MGMT and TAMs was evalu-
ated in 161 GBM patients, who were stratified based
on MGMT methylation status and total IBA-1 or total
CD204. High AF IBA-1TOTAL levels tended to associate
with shorter survival in patients with methylated
MGMT promoter (m-MGMT) (HR = 1.26; 95% CI:
0.98–1.60; P = 0.065), while no association was found
for MI IBA-1TOTAL (HR = 0.83; 95% CI: 0.61–1.13;
P = 0.23) (Figure 4E,F). In the patients with unmethy-
lated MGMT promoter (u-MGMT), both high AF IBA-
1TOTAL and high MI IBA-1TOTAL levels were associated
with better outcome (HR = 0.80; 95% CI: 0.64–0.99;
P = 0.036 and HR = 0.72; 95% CI: 0.54–0.95;
P = 0.020) (Figure 4E,F). In the m-MGMT group,
patients with high AF CD204TOTAL had poorer progno-
sis than patients with low AF CD204TOTAL (HR = 1.38;
95% CI: 1.07–1.77; P = 0.009), while this was not the
case in the u-MGMT group (HR = 1.06; 95% CI: 0.85–
1.31; P = 0.61) (Figure 4G). In patients with m-
MGMT, high MI CD204TOTAL was associated with
shorter survival (HR = 1.67; 95% CI: 1.12–2.51;
P = 0.009), whereas the prognostic value was less evi-
dent in patients with u-MGMT (HR = 1.34; 95% CI:
1.00–1.78; P = 0.043) (Figure 4H).
When MGMT status was included in the multivariate
analysis, AF IBA-1TOTAL and MI IBA-1TOTAL were
insignificant regarding prognosis, whereas high levels
of both AF CD204TOTAL (HR = 1.66; 95% CI: 1.16–
2.37; P = 0.005) and MI CD204TOTAL (HR = 2.11;
95% CI: 1.31–3.40; P = 0.002) predicted poorer OS
(Table 2). Similar was found for both high AF
CD204IBA-1 and MI CD204IBA-1 (data not shown).
TAMs and tumour heterogeneity
GBMs displayed intertumoural (Figure 5A–C) and intra-
tumoural (Figure 5D) heterogeneity in terms of the
expression of IBA-1 and CD204. IBA-1+ and/or
CD204+ TAMs tended to accumulate in perivascular
areas (Figure 5E,F), pseudopalisading necroses (Fig-
ure 5G) and perinecrotic areas (Figure 5H). In the
tumour periphery, TAMs primarily expressed IBA-1
and appeared more ramified compared with the central
tumour where they often had an amoeboid morphol-
ogy. Interestingly, some double-positive TAMs were
seen at the edge between central tumour and tumour
periphery (Figure 5I). Quantified, the amount of TAMs
was lower in the periphery compared with the central
zone (P < 0.01 or P < 0.05) (Figure 5J and Table S6).
The IBA-1 intensity was similar in the two areas, while
the CD204 intensity decreased from the central to the
peripheral tumour area (P < 0.05) (Figure 5K and
Table S6).
The relation between TAMs and the presence of
gemistocytes was examined by assessing the gemisto-
cytic cell component in 48 astrocytomas (11 DAs, 17
AAs and 20 GBMs). High amounts of CD204 and
high AF IBA-1TOTAL positively correlated with gemis-
tocytic score. Contrarily, in GBMs, high MI IBA-
1TOTAL inversely correlated with gemistocytic score
(Table S7).
To estimate the associations between tumour subtype
and TAMs, 20 GBMs were immunohistochemically sub-
typed using three proneural and three mesenchymal
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markers (Figure 5L). The mesenchymal tumours gener-
ally had higher levels of AF IBA-1TOTAL (P = 0.022)
and CD204 (P < 0.001) (Figure 5M,N) and a higher
gemistocytic score (P = 0.020) (Table S6), whereas the
proneural tumours showed higher levels of MI IBA-
1TOTAL (P = 0.012) (Figure 5N and Table S6). In addi-
tion, high AF CD204TOTAL (HR = 2.91; 95% CI: 1.03–
8.18; P = 0.035) and the mesenchymal subtype
(HR = 2.97; 95% CI: 1.01–8.76; P = 0.040) showed
similar survival curves, and both correlated with
decreased OS (Figure 5O).
TAMs and CD204 phenotype
To explore the phenotype of CD204+ TAMs in patient
tissue, we performed double immunofluorescence with
CD204 and markers related to inflammation and
immune activation, as well as to infiltration, prolifera-
tion, angiogenesis and necrosis (Figure 6A–H)
[8,9,11,21,51]. On average, 44% and 8% of the
CD204+ area co-expressed the marker major histocom-
patibility complex class II (HLA-DR) and tumour necro-
sis factor alpha (TNF-a), respectively (Figure 6A,B,I),
while 10% and 3% co-localization was seen with the
anti-inflammatory markers interleukin 10 (IL10) and
transforming growth factor beta1 (TGF-b1) (Figure 6C,
D,I). Most of the CD204+ area co-expressed matrix met-
allopeptidase 14 (MMP14). Average co-expression of
hypoxia-inducible factor-1alpha (HIF-1a) was 13%.
VEGF and CD204 rarely overlapped, whereas 9% of the
CD204+ area co-localized with epidermal growth fac-
tor receptor (EGFR) (Figure 6E–I). A comparable
scatter plot was found when measuring the intensity of
the marker of interest within the CD204+ area (Fig-
ure S4).
CD204+ cells did not express glial fibrillary acidic
protein, OLIG-2, microtubule-associated protein 2, or
smooth muscle actin indicating that tumour cells and
vascular smooth muscle cells do not contribute to the
CD204+ cell population (Figure S4).
Patient databases
We evaluated two bioinformatics databases, validating
that both IBA-1 and CD204 increased with malignancy
grade (Figure S5A,B). In the Glavendeel and TCGA
datasets, high CD204 mRNA levels correlated with
poorer prognosis in GBM (HR = 1.41; 95% CI: 1.01–
1.95; P = 0.039 and HR = 1.29; 95% CI: 1.05–1.57;
P = 0.013) (Figure S5C,D). As expected, the mesenchy-
mal subtype had the highest level of CD204 compared
with the proneural and classical subtypes (P < 0.001)
(Figure S5E,F).
Discussion
This study shows that M2-like TAMs predict poorer
prognosis in high-grade glioma and are associated with
more aggressive tumours as these cells are more fre-
quent in tumours with high gemistocytic cell count
and in GBMs of the mesenchymal subtype. Characteriz-
ing the M2-like TAMs in patient-derived GBM tissue
revealed that M2-like TAMs may contribute to a
tumour microenvironment favouring especially tumour
infiltration and expansion, but also angiogenesis and
tumour resistance (Figure 7).
We found that CD204 and IBA-1 levels increased
with malignancy. This is in accordance with other
studies on primary gliomas using general TAM markers
CD68 [15,26,28] and IBA-1 [27,28], as well as M2
markers CD163 and CD204 [15]. Prosniak et al. [30],
too, showed malignancy to correlate with high expres-
sion of M2-related molecules including IL-10, TGF-b,
CD163 and CD204 at mRNA levels and/or immunohis-
tochemically using human glioma specimens. However,
these studies primarily used semi-quantitative scoring,
and fewer patients (between 32 and 107 patients) were
included.
The acquired phenotype of TAMs was found to affect
prognosis, while the general amount of TAMs was less
important as the fraction of IBA-1+ in the total tumour
Figure 4. The association between tumour-associated microglia/macrophages and postsurgical treatment or MGMT methylation status.
(A–D) Patients with glioblastoma (n = 193) were stratified based on whether they had received postsurgical treatment and on (A) AF
IBA-1TOTAL, (B) MI of IBA-1TOTAL, (C) AF CD204TOTAL or (D) MI of CD204TOTAL. (E–F) Patients with glioblastoma (n = 161) were
stratified based on MGMT methylation status and on the (E) AF IBA-1TOTAL, (F) MI of IBA-1TOTAL, (G) AF CD204TOTAL or (H) MI of
CD204TOTAL. AF, area fraction; IBA-1, ionized calcium-binding adaptor molecule-1; MGMT, O6-methylguanine–DNA methyl-
transferase; m-MGMT, methylated MGMT promoter; MI, mean intensity; u-MGMT, unmethylated MGMT promoter; PST, postsurgical
treatment.
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area (AF IBA-1TOTAL) did not influence OS. The IBA-1
intensity, however, seemed to correlate with better out-
come in patients grade II, III and IV gliomas. In con-
trast, high amounts of CD204 predicted poorer survival
in WHO grade III–IV gliomas, but not in grade II
tumours. This was confirmed in two bioinformatics
databases. Previous studies have shown that high
CD163/CD68 [15] and CD163/IBA-1 ratios [29] as
well as high CD163 content [30] predict shorter sur-
vival in high-grade gliomas. We used CD204 to identify
M2 TAMs as CD163 is only reliable as a M2 marker
when in combination with the transcription factor
Table 2. Multivariate Cox regression analyses of IBA-1 and CD204 levels in patients with WHO grade IV tumours including clinical
parameters and MGMT status
No. of patients
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Baseline model AF IBA-1TOTAL MI IBA-1TOTAL
Age 161 1.01 (1.00–1.03) 0.13 1.01 (1.00–1.03) 0.15 1.01 (0.99–1.03) 0.17
Performance status
0–1 100 1.00 1.00 1.00
2–4 61 1.43 (1.25–1.64) <0.001 1.43 (1.25–1.64) <0.001 1.41 (1.23–1.62) <0.001
Tumour crossing midline
No 148 1.00 1.00 1.00
Yes 13 1.78 (0.97–3.27) 0.064 1.79 (0.97–3.31) 0.064 1.76 (0.95–3.24) 0.071
Postsurgical treatment
Stupp* 92 1.00 1.00 1.00
PC† 40 1.45 (0.95–2.21) 0.084 1.45 (0.95–2.22) 0.084 1.52 (0.99–2.33) 0.056
None‡ 29 9.50 (5.35–16.9) <0.001 9.55 (5.36–17.0) <0.001 9.83 (5.55–17.4) <0.001
MGMT methylation status
Unmet 88 1.00 1.00 1.00
Met 73 0.85 (0.59–1.23) 0.40 0.85 (0.58–1.24) 0.40 0.86 (0.60–1.24) 0.42
AF/MI
Low – – 1.00 1.00
High – – – 0.98 (0.69–1.38) 0.89 0.75 (0.49–1.15) 0.18
AF CD204TOTAL MI CD204TOTAL
Age 161 – – 1.02 (1.00–1.03) 0.086 1.01 (1.00–1.03) 0.099
Performance status
0–1 100 – 1.00 1.00
2–4 61 – – 1.47 (1.28–1.69) <0.001 1.40 (1.22–1.61) <0.001
Tumour crossing midline
No 148 – 1.00 1.00
Yes 13 – – 1.74 (0.94–3.22) 0.076 1.85 (1.00–3.41) 0.051
Postsurgical treatment
Stupp* 92 – 1.00 1.00
PC† 40 – – 1.67 (1.08–2.58) 0.022 1.47 (0.96–2.25) 0.078
None‡ 29 – – 8.63 (4.88–15.3) <0.001 10.4 (5.81–18.8) <0.001
MGMT methylation status
Unmet 88 1.00 1.00 1.00
Met 73 0.96 (0.66–1.39) 0.82 0.89 (0.61–1.28) 0.52
AF/MI
Low – – 1.00 1.00
High – – – 1.66 (1.16–2.37) 0.005 2.11 (1.31–3.40) 0.002
IBA-1, ionized calcium-binding adaptor molecule-1; WHO, World Health Organization; AF, area fraction; MI, mean intensity; PC, pallia-
tive care; MGMT, O6-methylguanine–DNA methyltransferase.
*Treatment according to the publication by Stupp et al. [1].
†Palliative treatment is radiotherapy alone (60 Gy/30–33 fractions), hypofractionated radiotherapy alone (30–34 Gy/10 fractions),
hypofractionated radiotherapy with chemotherapy, or chemotherapy alone.
‡No postsurgical treatment.
Bold values represent the significant P values (P < 0.05)
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V-maf avian musculoaponeurotic fibrosarcoma onco-
gene homologue (c-MAF) [51,52]. Further, assessing
the general population of TAMs with CD68 may be
problematic. Reportedly, M1 macrophages express high
levels of CD68 [51], and recently, CD68 expression was
found in many cases to be lower compared with
CD163 in GBMs [52,53]. In addition, CD68 was shown
to be expressed by some human glioma cells [54,55].
Overall, these findings question its suitability as a gen-
eral marker of TAMs.
In our study, we included more patients compared to
previous prognostic studies on TAMs in gliomas [15,
(A) (B) (C) (D)
(E)
(I) (J)
(L) (M) (N) (O)
(K)
(F) (G) (H)
Figure 5. Tumour-associated microglia/macrophages (TAMs) heterogeneity in glioblastomas. (A–D) Phenotypic differences in ionized
calcium-binding adaptor molecule-1 (IBA-1) (red) and CD204 (green) expression were seen between tumours (A–C) and within the
individual tumour (D). Arrows indicate double-positive cells. (E–H) Besides expression in viable tumour tissue, TAMs were also present
around blood vessels (Asterisk) (E,F) and in perinecrotic areas including pseudopalisading necroses (Plus) (G,H) often in clusters. (I) The
density of TAMs, especially CD204+ TAMs, was higher in the central tumour (insert 1) compared with the border zone (insert 2) and the
tumour periphery (insert 3). (J,K) The amount of CD204 was significantly lower in the tumour periphery compared with central tumour.
(L) Tissue from 20 patients with glioblastoma was immunohistochemically subtyped using three proneural markers [PN, shown for
oligodendrocyte transcription factor 2 (OLIG-2)] and three mesenchymal markers (MES, shown for CD44). (M,N) Especially CD204
expression was higher in the mesenchymal than in the proneural subtype. (O) Survival curve for the 20 patients with glioblastoma based
on the area of CD204 in total tumour area (area fraction CD204TOTAL) and subtype. Horizontal and vertical lines indicate mean  SEM.
*P < 0.05; **P < 0.01; ***P < 0.001. Scale bar 100 lM.
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26–28,30]. However, our study also had a limited num-
ber of patients with grade II–III gliomas and may not be
representative for the entire population. The statistical
analyses should, thus, be interpreted with caution.
In our multivariate analyses, CD204 was an indepen-
dent predictor of poor OS in grade III–IV tumours. Simi-
lar has been reported in carcinomas including
pancreatic [56,57], bladder [58] and lung cancers [59],
Figure 7. Schematic illustration of the presumed cross-talk between glioblastoma cells and M2-like TAMs. In the tumour
microenvironment, M2-like tumour-associated microglia/macrophages expressing high amounts of CD204 with lower levels of ionized
calcium-binding adaptor molecule-1 and HLA-DR interact with the glioblastoma cells favouring a mesenchymal shift in the tumour cells.
The M2-like TAMs produce MMP14, HIF-1a, IL10, EGFR and TNF-a possibly stimulating angiogenesis and especially matrix remodelling.
With scavenger functions of CD204, e.g. clearance of myelin, extracellular matrix components and apoptotic cells, M2-like TAMs may
ultimately enable tumour infiltration and progression. G, gemistocytes; TAM, tumour-associated microglia; TAMФ, tumour-associated
macrophage; MES, mesenchymal glioblastoma cells; IL10, interleukin 10; TNF-a, tumour necrosis factor alpha; EGFR, epidermal growth
factor receptor; MMP14, matrix metallopeptidase 14; HLA-DR, human leucocyte antigen DR/major histocompatibility complex class II
DR; HIF-1a, hypoxia-inducible factor-1alpha.
Figure 6. Characterization of CD204+ tumour-associated microglia/macrophages. (A–H) The phenotype of the CD204+ cells (green) was
investigated using markers related to M1 polarization: HLA-DR (red) and TNF-a (red) (A, B), M2 polarization: IL10 (red) and TGF-b1
(red) (C, D) as well as to tumour aggressiveness: MMP-14 (red), HIF-1a (red), VEGF (red) and EGFR (red) (E-H). (I) For the marker of
interest, the double-positive area was quantified as a percentage of the total CD204+ area. Arrows and inserts show double-positive cells.
Horizontal and vertical lines indicate mean  SEM. Scale bar 100 lM. HLA-DR, human leucocyte antigen DR/major histocompatibility
complex class II DR; TNF-a, tumour necrosis factor alpha; IL10, interleukin 10; TGF-b1, transforming growth factor beta1; MMP-14,
matrix metallopeptidase 14; HIF-1a, hypoxia-inducible factor-1alpha; VEGF, vascular endothelial growth factor; EGFR, epidermal growth
factor receptor.
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while no independent prognostic value was found of
CD204+ TAMs in oesophageal cancer [60] or in primary
CNS lymphoma [61]. Contradictory results have been
reported in colorectal cancer [62–64], but in gastric
[65] and ovarian cancer [66] high density of M1 TAMs
and high M1/M2 ratio were associated with longer sur-
vival, whereas M2 TAMs themselves (identified with a
CD163 antibody) showed no influence on prognosis.
Zhang et al. [64] conducted a meta-analysis on solid
tumours analysing primarily the impact of CD68+ TAMs
and found that a high density of TAMs in most cancers
appears to associate with poorer OS. Summarized, the
prognostic value of TAMs may differ among and within
the different cancers dependent on the tumour microen-
vironment, but also on the specific marker used to iden-
tify them. Most research including our results indicates
that M2 TAMs favour tumour progression.
TAMs were heterogeneously distributed in gliomas at
the inter- and intratumoral level. This is possibly
explained by the predominant cellular component in
the tumours and the molecular subclass of the glioma.
For the first time, we report that CD204+ TAMs at a
protein level are more abundant in astrocytomas with
large fractions of gemistocytes and in GBMs of the mes-
enchymal subtype. This is comparable to previous
results reporting a positive correlation between micro-
glial and gemistocytic index in grade II–IV gemistocytic
astrocytomas [67]. Further, at the mRNA level, TAM-
related markers were enriched in GBMs with a mes-
enchymal molecular signature [45,68], and similar
correlations were reported for tumour-infiltrating lym-
phocytes [69]. High frequency of gemistocytes has been
linked to higher probability of tumour protein 53
mutations, B-cell lymphoma 2 expression and tumour
progression/recurrence [70,71], while the mesenchy-
mal subtype is associated with high degrees of necrosis,
poorer patient prognosis, treatment resistance and is
the most frequent subtype in recurrent GBMs
[45,46,72]. Overall, this suggests that TAMs and espe-
cially M2 TAMs may contribute to tumour progression
by stimulating the development of more aggressive
tumours.
The M2-related marker CD204 belongs to the scav-
enger receptor family and is capable of binding and
internalizing a range of ligands including apoptotic
cells and chemically modified or altered molecules, for
example, low-density lipoproteins, collagen and myelin
[73,74]. Consistent with its function and with previous
observations [73], normal brain tissue had low levels
of CD204. In GBMs, the amount and intensity of
CD204 varied with some tumours expressing predomi-
nantly CD204 compared with IBA-1. IBA-1 is a gen-
eral microglia/macrophage marker [75], but the
expression level is upregulated upon cellular activation,
and high levels of IBA-1 are associated with increased
cell motility [31,76] and pro-inflammatory activity in
macrophages [77,78]. Further, in Alzheimer’s pathol-
ogy, IBA-1 expression correlated with absence of
dementia and better cognitive function possibly
explained by a higher level of microglial active surveil-
lance, while the opposite correlations were found for
CD204 [79]. Analysing the relation between IBA-1
and CD204, we found an inverse correlation between
the intensity levels (data not shown), and survival
analysis showed that TAMs with IBA-1LOW/CD204HIGH
phenotype correlated with worse patient outcome,
overall indicating that TAMs with IBA-1HIGH pheno-
type may represent a population of activated TAMs
which have not been polarized in the M2 direction and
that the extent of M2 polarization is important. Most
research indicates that M2 macrophages are a hetero-
geneous population that can be divided into M2a, M2b
and M2c subsets [80]. Gabrusiewicz et al. [21] showed
that CD204 is mainly augmented in M2a and M2c
macrophages in vitro. When we investigated the func-
tional properties of the CD204+ TAMs, we found con-
junctionally expression of proteins related to M1 (HLA-
DR, TNF-a) and M2 (IL-10, TGF-b1) activation. Our
data contradict in vitro findings performed on rodent
microglia arguing that M2 TAMs produce more TGF-
b1 and IL10 compared with TNF-a [16,81,82], as we
found little to moderate overlap between CD204 and
all three cytokines. Our data indicate that TAMs can-
not be delimited into a classical M1 or M2 activation
state, but represent a unique phenotype. This is sup-
ported by recent microarray and RNA sequencing data
on TAMs isolated from murine and human gliomas
[17–21] and by results found in pancreatic cancer
[83]. Reportedly, M2 TAMs show reduced expression of
HLA-DR resulting in poorer antigen presentation
[9,51], although the downregulation of the co-stimula-
tory molecules CD80 and CD86 may be of greater
importance [13,14]. We only found 50% co-expression
between CD204 and HLA-DR indicating an overall
impaired ability to present antigens. However, the
range of HLA-DR co-expression was between 3% and
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85% suggesting that a subset of M2 TAMs resembled
the HLA-DR myeloid-derived suppressor cells
(MDSCs), while another subset resembled a more classi-
cal HLA-DRHIGH M1 phenotype. This reflects the
heterogeneity also among M2 TAMs and indicates that
their polarization might depend on the location of the
specific TAM within the tumour tissue as wells its
specific cellular origin (macrophages vs. microglia vs.
MDSCs) and on the stage of disease.
M2 TAMs may contribute to treatment resistance
In GBM patients, CD204+ TAMs correlated with poorer
survival in patients receiving postsurgical treatment.
When we included MGMT methylation, high amounts
of CD204 also predicted poorer survival in patients
with MGMT methylated promoters, while the survival
detriment was less evident in patients with unmethy-
lated MGMT promoters. This suggests that M2 TAMs
contribute to treatment resistance in GBMs. The impor-
tance of myeloid cells including TAMs in the therapeu-
tic response in cancer has recently been reviewed [84].
In GBMs, tumour resistance has also been linked to
tumour hypoxia [6,85]. Supported by previous reports
[86–88], we observed that TAMs accumulated in areas
of hypoxia, and when investigating the phenotype of
CD204+ cells, we found up to 50% co-expression with
HIF-1a. Reportedly, hypoxic conditions induce a mes-
enchymal shift in GBMs [85,89] and fine-tune the M2
polarization of TAMs [90], leading to an upregulation
of HIFs and HIF target genes by TAMs including MMPs
and proangiogenic factors, for example, TNF-a [86,87].
In a breast carcinoma model, the tumour volume was
reduced, and docetaxel proved more effective when the
tumour environment contained HIF-1a knockout
macrophages as compared with a microenvironment
with wild-type macrophages [91]. In summary, this
suggests that TAMs and hypoxia co-ordinate a
microenvironment favouring tumour resistance and
progression.
Primarily, IBA-1+ TAMs were present in the tumour
periphery, whereas CD204+ TAMs were restricted to
the central tumour and the area adjacent to the
tumour periphery, suggesting that M2 TAMs may con-
tribute to tumour invasiveness. This is in agreement
with a study in which TAMs were found to reside at
the invasive front [82]. Our immunofluorescence char-
acterization of the CD204+ TAMs revealed a substantial
co-expression of MMP-14, which reportedly acts as a
co-factor for extracellular matrix breakdown and
tumour expansion [8,9,22,24] as well as of EGFR
which has been linked to increased tumour invasive-
ness and proliferation/survival [24,25]. Together with
the scavenger function of CD204, this indicates that
TAMs co-expressing CD204 and MMP14 may be effec-
tive mediators of matrix remodelling facilitating tumour
infiltration.
Conclusions
Recent genetic profiling of TAMs in human GBM indi-
cates that TAMs can take on several phenotypes along
the M1-M2 spectrum including the more undifferenti-
ated M0 state [21]. Our results demonstrate that the
prognostic impact of TAMs in gliomas does not depend
on the total amount of TAMs, but on their acquired
functional phenotype. High levels of the M2-related
marker CD204 correlated with increasing malignancy
grade and poor patient survival in WHO grade III and
IV independently of clinical-pathological parameters.
CD204+ TAMs were associated with a more aggressive
tumour subtype and expressed proteins that could
enable tumour progression. These results highlight the
significant existence of TAMs in the tumour microenvi-
ronment and demonstrate that quantitative assessment
of CD204 is feasible and potentially a clinically valu-
able prognostic biomarker in high-grade gliomas. Dee-
per insight into the impact of TAMs in gliomas may
open new possibilities and expand the field of treatment
strategies using TAMs as novel targets.
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